Topical resiquimod: A promising adjuvant for vaccine development?

Expert Review of Vaccines

Volumn 9, Issue 1, 2010, Pages 23-27

  Igartua, Manoli ^a   Pedraz, José Luís ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Adjuvant; CTL response; Resiquimod; Toll like receptor

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYXOVIRUS RESISTANCE PROTEIN A; OVALBUMIN; PLACEBO; RESIQUIMOD; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADJUVANT THERAPY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG SAFETY; MELANOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

EID: 74349122739     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.135     Document Type: Note

References (31)

1. Chang BA, Cross JL, Najar HM, Dutz JP. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27(42), 5791-5799 (2009).
2. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 25(19), 3752-3762 (2007).
3. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364(2), 272-280 (2008).
4. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant - "The long and winding road". Drug Discov. Today 14(11/12), 541-551 (2009).
5. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27(25-26), 3331-3334 (2009).
6. Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21(1), 23-29 (2009).
7. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-58 (2006).
8. Manicassamy S, Pulendran B. Modulation of adaptative immunity with Toll-like receptors. Semin. Immunol. 21, 185-193 (2009).
9. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Inmmunobiology 211, 599-608 (2006).
10. Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 29(2), 272-282 (2008).
11. Garlapati S, Facci M, Polewicz M et al. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet. Immunol. Immunopathol. 128(1-3), 184-191 (2009).
12. Lahiri A, Das P, Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26(52), 6777-6783 (2008).
13. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24(11), 1958-1965 (2006).
14. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin. Investig. Drugs 17(7), 1051-1065 (2008).
15. Tomai MA, Miller RL, Lipson KE, Vasilakos JP, Woulfe SL. Immune response modifiers: imiquimod and future drugs for modulating the immune response. Drug Discov. Today 3, 343-352 (2006).
16. Tomai MA, Miller RL, Lipson KE et al. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines 6(5), 835-847 (2007).
17. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25(3-4), 135-154 (2006).
18. Najar HM, Dutz JP. Topical TLR9 agonists induce more efficient crosspresentation of injected protein antigen than parenteral TLR9 agonists do. Eur. J. Immunol. 37, 2242-2256 (2007).
19. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61(3), 195-204 (2009).
20. Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 22(13-14), 1782-1790 (2004).
21. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22(13-14), 1799 - 1809 (2004).
22. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine 23(45), 5263-5270 (2005).
23. Zhang W, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76(8), 3777-3783 (2008).
24. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174(5), 2476-2480 (2005).
25. Othoro C, Johnston D, Lee R, Soverow J, Bystryn J, Nardin E. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77(2), 739-748 (2009).
26. Wilson NS, Behrens GM, Lundie RJ et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7(2), 165-172 (2006).
27. + T cell response during cross-priming. J. Immunol. 176(8), 4682-4689 (2006).
28. Perry JA, Olver CS, Burnett RC, Avery AC. Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J. Immunol. 174(10), 5921-5925 (2005).
29. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108(10), 3253-3261 (2006).
30. Gunzer M, Riemann H, Basoglu Y et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 106(7), 2424-2432 (2005).
31. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng T. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47(12), 3846-3852 (2003).